ESMO Virtual 2020: Biomarker-guided therapy in metastatic kidney cancer

Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were presented at the European Sociaety of Medical Oncology (ESMO) virtual congress. The study showed clinical evidence that biomarker-guided first-line therapy could be used to enrich responses in patients with metastatic clear cell renal cell carcinoma (RCC). The trial included 154 patients treated with nivolumab or […]

read more

ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer

Non-clear cell renal cell carcinoma (RCC) accounts for about 25% of all RCC diagnoses and usually has worse outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have shown preliminary activity in non-clear cell RCC. Cabozantinib appears to enhance the response to immune checkpoint inhibitors and has shown encouraging results in combination with […]

read more

ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer

At the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Dr Choueiri from Dana Farber Cancer Institute in Boston, USA presented the results of the phase 3 CheckMate-9ER trial evaluating the combination of nivolumab and cabozantinib compared to sunitinib in the first-line treatment of patients with advanced or metastatic renal cell carcinoma (RCC). Each […]

read more

PBRM1 as a biomarker for kidney cancer

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Centre in Texas, USA, talks about the use of PBRM1 as a potential biomarker for immune response to checkpoint inhibitors. The data for this biomarker is controversial and complicated and in the future researchers need to better understand how this relates to treatment response. […]

read more

ESMO Virtual 2020: Treatment-free survival after immunotherapy vs. targeted therapy for advanced kidney cancer

Over the past 2 years, the use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has become the standard of care for these patients. The first combination was nivolumab plus ipilimumab, which demonstrated a survival benefit over sunitinib in patients with intermediate and poor risk metastatic RCC (CheckMate-214). Shortly after, […]

read more

ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer

Over the past 2 years, the use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has become the standard of care for these patients. The first combination was nivolumab plus ipilimumab, which demonstrated a survival benefit over sunitinib in patients with intermediate and poor risk metastatic RCC (CheckMate-214). Shortly after, […]

read more

First-line treatment of kidney cancer

These two videos with Dr Eric Jonasch from MD Anderson Cancer Center and Dr Elizabeth Plimack from Fox Chase Cancer Centre, both in the USA, explain how clinicians choose between the first-line treatments that are available for the treatment of renal cell carcinoma (RCC) and the long term control of the disease. Watch the video […]

read more

Gut microbes linked with immunotherapy response in kidney cancer

A recent study published in European Urology had shown that the diversity of microbes in the gut is associated with better outcomes in people with metastatic renal cell carcinoma (RCC) who are taking immunotherapy. There are numerous bacteria and viruses in the gut, called the microbiome. This gut microbiome is increasingly linked to health and […]

read more

Advances in systemic treatments for metastatic kidney cancer

In this video interview Professor Jens Bedke from the Department of Urology, Eberhard Karls University Tübingen in Germany discusses the transformation in the first-line treatment of renal cell carcinoma (RCC) from tyrosine kinase inhibitors (TKIs), which was the standard of care, to combination therapies. First-line treatment with a combination of an immune checkpoint inhibitor and […]

read more

Treatment of brain metastases for kidney cancer patients

Brain metastases in patients with renal cell carcinoma (RCC) is actually fairly uncommon, occurring in around 8% to 10% of all patients with metastatic RCC. Unfortunately, RCC brain metastases have been poorly studied and have a poor outcome, often with a median overall survival as low as 3 months in people with multiple brain metastases. […]

read more
Showing 1 to 10 of 245 results
  TOP